Effect of Different Concentrations of Xylitol and Erythritol on Gut Peptide Release and Gastric Emptying in Humans
- Conditions
- Physiological Satiation Mechanisms
- Interventions
- Dietary Supplement: Xylitol 7gDietary Supplement: Xylitol 35gDietary Supplement: Xylitol 17gDietary Supplement: Erythritol 25gDietary Supplement: Erythritol 50gDietary Supplement: Erythritol 10g
- Registration Number
- NCT03039478
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Brief Summary
Xylitol and erythritol have become increasingly popular as sugar substitutes in the food industry. Both substances are freely available. While glucose ingestion stimulates satiation hormone secretion in the gut and slows down gastric emptying, artificial sweeteners such as aspartame, sucralose and acesulfame-K have no such effect. However, acute intake of 50g xylitol or 75g erythritol in 300mL tap water leads to a marked increase in the satiation hormones and induces a significant retardation in gastric emptying. The concentrations used to Show this effect were rather high (50g xylitol and 75g erythritol) and led to bloating and diarrhea in 60-70% of all subjects two hours after administration. The aim of the present study is to find an effective concentration of xylitol and erythritol still stimulating satiation hormone release without any gastrointestinal adverse events.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
- Healthy normal weight subjects with a body-mass index of 19.0-24.9
- Normal eating habits (no diets; no dietary changes; no special dietary habits, such as vegetarian/vegan)
- Age 18-40 years
- Stable body weight for at least three months
- Informed Consent as documented by signature
- Pre-existing consumption of xylitol or erythritol on a regular basis (usage of xylitol or erythritol as sugar replacement; xylitol or erythritol containing toothpaste is allowed)
- Regular intake of medications (except for oral contraceptives)
- Evidence of relevant cardiovascular, pulmonary, renal, hepatic, pancreatic, gastrointestinal, metabolic, endocrinological, neurological, psychiatric or other diseases at screening
- Clinically relevant abnormalities in haematological laboratory parameters
- Food allergies, food intolerance
- Pregnancy
- Participation in another study with investigational drug within the 30 days preceding and during the present study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Xylitol 7g in 300mL tap water Xylitol 7g 12 volunteers receive 7g xylitol in 300mL tap water via a nasogastric tube Xylitol 35g in 300mL tap water Xylitol 35g 12 volunteers receive 35g xylitol in 300mL tap water via a nasogastric tube Xylitol 17g in 300mL tap water Xylitol 17g 12 volunteers receive 17g xylitol in 300mL tap water via a nasogastric tube Erythritol 25g in 300mL tap water Erythritol 25g 12 volunteers receive 25g erythritol in 300mL tap water via a nasogastric tube Erythritol 50g in 300mL tap water Erythritol 50g 12 volunteers receive 50g erythritol in 300mL tap water via a nasogastric tube Erythritol 10g in 300mL tap water Erythritol 10g 12 volunteers receive 10g erythritol in 300mL tap water via a nasogastric tube
- Primary Outcome Measures
Name Time Method Acute effect on cholecystokinin ( CCK) release changes from baseline to three hours after treatment effect on CCK release measured by a commercially available ELISA kit (enzyme-linked immunosorbent assay)
- Secondary Outcome Measures
Name Time Method Acute effects on gastric emptying changes from baseline to three hours after treatment Acute effects on gastric emptying measured by 13C-sodium-acetate breath test
Acute effects on subjective feelings of hunger and satiety changes from baseline to three hours after treatment Acute effects on subjective feelings of hunger and satiety measured by visual analogue scales
Trial Locations
- Locations (1)
University Hospital Basel
🇨🇭Basel, Switzerland